#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Wiskott-Aldrich syndrome Acute graft versus host disease in intestine Penile squamous cell carcinoma Leiomyosarcoma recurrent Follicular lymphoma stage III Adenovirus infection Dermatitis Prolymphocytic leukaemia Duchenne muscular dystrophy Chemical burn Mitochondrial encephalomyopathy Dilated cardiomyopathy Niemann-Pick disease Hepato-lenticular degeneration Measles More trials…

    Learn about Rare Diseases

    Piriformis syndrome Nephroblastoma – Life with Disease Mucopolysaccharidosis I – Trials in Disease Urea cycle disorder – Basic Information Cholangitis sclerosing – Trials in Disease Marginal zone lymphoma Ornithine transcarbamoylase deficiency – Life with Disease Toxic epidermal necrolysis – Life with Disease Vascular malformation – Life with Disease Familial amyotrophic lateral sclerosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mirodenafil Dihydrochloride Englumafusp Alfa Ly3819469 Sodium VGA039 Ganciclovir Sodium Ropivacaine Odevixibat Enlicitide Chloride Domperidone Ziftomenib DCC-3084 Abc-15A-116 Xaluritamig GRNA1599 Mva-209-Fsp-B3 Betamethasone Acetate Dfv890 LUTETIUM LU-177 Gskvx000000008885 Zanubrutinib More therapies…

    Learn about Your Condition

    Endometrial cancer stage III Aneurysm ruptured Genital infection female Osteogenesis imperfecta Large cell lung cancer stage 0 Myelodysplastic syndrome Desmoid tumour Cardiovascular disorder Colon cancer stage IV Myotonia Ligament operation Hip fracture Liver transplant Renal cancer recurrent Colitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of Olaparib for Patients with Advanced Cancer Having HRRm or HRD Mutations

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Olaparib
    Denmark France Ireland Italy Romania Spain

  • Study on the Safety and Effectiveness of ALLO-501A and ALLO-647 for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Allo-501A
    • Allo-647
    • Letermovir
    Italy Spain

  • Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Allo-501A
    • Allo-647
    • Letermovir
    Austria Belgium Germany

  • Study on Ganaxolone for Patients with Refractory Status Epilepticus

    Not recruiting

    3 1
    Investigated Diseases:
    • Status epilepticus
    Investigated Drugs:
    • Ganaxolone
    Austria Belgium Croatia Czechia Denmark Finland +8

  • Study on the Effects of Leriglitazone for Adult Men with Cerebral Adrenoleukodystrophy

    Not recruiting

    3 1
    Investigated Diseases:
    • Adrenoleukodystrophy
    Investigated Drugs:
    • Leriglitazone
    France Germany Spain

  • Study on the Effects of Maridebart Cafraglutide for Adults with Type 2 Diabetes

    Not recruiting

    2 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Greece Hungary Italy Poland Romania +2
Previous Page
1 … 1,656 1,657 1,658 1,659
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!